http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 10 Aug 2026 06:52:57 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/Emergent+BioSolutions+%28EBS%29+PT+Lowered+to+%2410+at+H.C.+Wainwright/26893933.html (Updated - August 10, 2026 6:52 AM EDT) <p>H.C. Wainwright analyst Raghuram Selvaraju lowered the price target on Emergent BioSolutions (NYSE: EBS) to $10.00 (from $12.00) while maintaining a Buy rating.</p><p>The analyst commented: "Late last week, Emergent BioSolutions reported its 2Q26 financial results. The company recorded $234.3M in top-line revenue for the period, well ahead of guidance and soundly beating our forecast for top-line revenue totaling only $175M. However, Emergent lowered its full-year 2026 revenue guidance to $645-675M vs. the prior guidance range of $720-760M. This is driven mainly by the outlook for the naloxone franchise, which is slated to undergo http://www.streetinsider.com/Analyst+PT+Change/Emergent+BioSolutions+%28EBS%29+PT+Lowered+to+%2410+at+H.C.+Wainwright/26893933.html Mon, 10 Aug 2026 06:52:57 -0400 EBS http://www.streetinsider.com/Analyst+Comments/Emergent+BioSolutions+%28EBS%29+PT+Lowered+to+%2410+at+H.C.+Wainwright/26893933.html (Updated - August 10, 2026 6:52 AM EDT) <p>H.C. Wainwright analyst Raghuram Selvaraju lowered the price target on Emergent BioSolutions (NYSE: EBS) to $10.00 (from $12.00) while maintaining a Buy rating.</p><p>The analyst commented: "Late last week, Emergent BioSolutions reported its 2Q26 financial results. The company recorded $234.3M in top-line revenue for the period, well ahead of guidance and soundly beating our forecast for top-line revenue totaling only $175M. However, Emergent lowered its full-year 2026 revenue guidance to $645-675M vs. the prior guidance range of $720-760M. This is driven mainly by the outlook for the naloxone franchise, which is slated to undergo http://www.streetinsider.com/Analyst+Comments/Emergent+BioSolutions+%28EBS%29+PT+Lowered+to+%2410+at+H.C.+Wainwright/26893933.html Mon, 10 Aug 2026 06:52:57 -0400 EBS http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Emergent+BioSolutions+++++For%3A+Jun+30/26877363.html si-local-file:///var/storage/secattach/20260806/26877363.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Emergent+BioSolutions+++++For%3A+Jun+30/26877363.html Thu, 06 Aug 2026 06:01:00 -0400 EBS O.01772186 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Emergent+BioSolutions+++++For%3A+Jun+30/26877363.html si-local-file:///var/storage/secattach/20260806/26877363.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Emergent+BioSolutions+++++For%3A+Jun+30/26877363.html Thu, 06 Aug 2026 06:01:00 -0400 EBS O.01772186 http://www.streetinsider.com/Earnings/Emergent+BioSolutions+%28EBS%29+Tops+Q2+EPS+by+49c/26876813.html <p>Emergent BioSolutions (NYSE: EBS) reported Q2 EPS of $0.60, $0.49 better than the analyst estimate of $0.11. Revenue for the quarter came in at $234.3 million versus the consensus estimate of $186 million.</p><p>For earnings history and earnings-related data on Emergent BioSolutions (EBS) <a href="http://www.streetinsider.com/ec_earnings.php?q=EBS">click here</a>.</p> http://www.streetinsider.com/Earnings/Emergent+BioSolutions+%28EBS%29+Tops+Q2+EPS+by+49c/26876813.html Thu, 06 Aug 2026 02:17:44 -0400 EBS http://www.streetinsider.com/Corporate+News/Emergent+BioSolutions+highlights+biological+threat+risks+amid+AI+advances/26874064.html <p>Emergent BioSolutions (NYSE: EBS) issued a statement Aug. 5, 2026, calling for cross-sector collaboration on biological threat preparedness, citing concerns about advances in artificial intelligence and synthetic biology.</p><p>The company referenced a letter signed in June 2026 by AI executives and cross-industry leaders urging Congress to require safety screening and recordkeeping for synthetic DNA and RNA orders. The letter stated that "AI systems are improving rapidly, and alongside incredible benefits to science and medicine, there is a real possibility that the knowledge barriers which have historically prevented bad actors from obtaining biological weapons will meaningfully erode."</p><p>Emergent also cited remarks by Sandra http://www.streetinsider.com/Corporate+News/Emergent+BioSolutions+highlights+biological+threat+risks+amid+AI+advances/26874064.html Wed, 05 Aug 2026 16:08:46 -0400 EBS http://www.streetinsider.com/Press+Releases/Emergent+BioSolutions+Reports+Second+Quarter+2026+Financial+Results/26874002.html <ul type="disc"><li style="margin-bottom:3pt; text-align:justify;">Second Quarter 2026 Total Revenues of $234.3 million, an improvement of 66% versus prior year</li><li style="margin-bottom:3pt; text-align:justify;">Second Quarter 2026 Net Loss of $180.2 million worsening 1,402% versus prior year, largely due to a $191.3 million non-cash impairment charge</li><li style="margin-bottom:3pt; text-align:justify;">Second Quarter 2026 Adjusted Net Income of $30.9 million improved 134% versus prior year</li><li style="margin-bottom:3pt; text-align:justify;">Second Quarter 2026 Gross Margin % of 50% and Adjusted Gross Margin % of 58%, an expansion of 1400 bps and 900 bps, respectively, versus prior year</li><li style="margin-bottom:3pt; text-align:justify;">Second Quarter 2026 Adjusted EBITDA of $96.5 million and Adjusted EBITDA Margin of 41%, an http://www.streetinsider.com/Press+Releases/Emergent+BioSolutions+Reports+Second+Quarter+2026+Financial+Results/26874002.html Wed, 05 Aug 2026 16:07:00 -0400 EBS http://www.streetinsider.com/Globe+Newswire/Emergent+BioSolutions+Reports+Second+Quarter+2026+Financial+Results/26874002.html <ul type="disc"><li style="margin-bottom:3pt; text-align:justify;">Second Quarter 2026 Total Revenues of $234.3 million, an improvement of 66% versus prior year</li><li style="margin-bottom:3pt; text-align:justify;">Second Quarter 2026 Net Loss of $180.2 million worsening 1,402% versus prior year, largely due to a $191.3 million non-cash impairment charge</li><li style="margin-bottom:3pt; text-align:justify;">Second Quarter 2026 Adjusted Net Income of $30.9 million improved 134% versus prior year</li><li style="margin-bottom:3pt; text-align:justify;">Second Quarter 2026 Gross Margin % of 50% and Adjusted Gross Margin % of 58%, an expansion of 1400 bps and 900 bps, respectively, versus prior year</li><li style="margin-bottom:3pt; text-align:justify;">Second Quarter 2026 Adjusted EBITDA of $96.5 million and Adjusted EBITDA Margin of 41%, an http://www.streetinsider.com/Globe+Newswire/Emergent+BioSolutions+Reports+Second+Quarter+2026+Financial+Results/26874002.html Wed, 05 Aug 2026 16:07:00 -0400 EBS http://www.streetinsider.com/Press+Releases/Emergent+BioSolutions+Commits+to+Cross-Sector+Collaboration+Against+Biological+Threats+in+an+Evolving+Global+Security+Environment/26874020.html <p>GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS), a global biodefense company, today highlighted the increasing importance of biological threat preparedness as allied nations confront an evolving security environment characterized by geopolitical conflict, artificial intelligence (AI) and synthetic biology and growing concern about the potential misuse of biological agents. Defense and public health leaders are addressing the heightened risks of biological incidents, whether naturally occurring outbreaks, accidental releases or deliberate acts, which represent a critical component of national resilience and security planning.</p> <p>In a recent event by the German Medical Association and German Ambulatory http://www.streetinsider.com/Press+Releases/Emergent+BioSolutions+Commits+to+Cross-Sector+Collaboration+Against+Biological+Threats+in+an+Evolving+Global+Security+Environment/26874020.html Wed, 05 Aug 2026 16:07:00 -0400 A.60012004 EBS O.01304637 O.01772186 http://www.streetinsider.com/Press+Releases/Emergent+BioSolutions+Commits+to+Cross-Sector+Collaboration+Against+Biological+Threats+in+an+Evolving+Global+Security+Environment/26874020.html <p>GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS), a global biodefense company, today highlighted the increasing importance of biological threat preparedness as allied nations confront an evolving security environment characterized by geopolitical conflict, artificial intelligence (AI) and synthetic biology and growing concern about the potential misuse of biological agents. Defense and public health leaders are addressing the heightened risks of biological incidents, whether naturally occurring outbreaks, accidental releases or deliberate acts, which represent a critical component of national resilience and security planning.</p> <p>In a recent event by the German Medical Association and German Ambulatory http://www.streetinsider.com/Press+Releases/Emergent+BioSolutions+Commits+to+Cross-Sector+Collaboration+Against+Biological+Threats+in+an+Evolving+Global+Security+Environment/26874020.html Wed, 05 Aug 2026 16:07:00 -0400 A.60012004 EBS O.01304637 O.01772186 http://www.streetinsider.com/Press+Releases/Emergent+BioSolutions+Commits+to+Cross-Sector+Collaboration+Against+Biological+Threats+in+an+Evolving+Global+Security+Environment/26874020.html <p>GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS), a global biodefense company, today highlighted the increasing importance of biological threat preparedness as allied nations confront an evolving security environment characterized by geopolitical conflict, artificial intelligence (AI) and synthetic biology and growing concern about the potential misuse of biological agents. Defense and public health leaders are addressing the heightened risks of biological incidents, whether naturally occurring outbreaks, accidental releases or deliberate acts, which represent a critical component of national resilience and security planning.</p> <p>In a recent event by the German Medical Association and German Ambulatory http://www.streetinsider.com/Press+Releases/Emergent+BioSolutions+Commits+to+Cross-Sector+Collaboration+Against+Biological+Threats+in+an+Evolving+Global+Security+Environment/26874020.html Wed, 05 Aug 2026 16:07:00 -0400 A.60012004 EBS O.01304637 O.01772186 http://www.streetinsider.com/Press+Releases/Emergent+BioSolutions+Commits+to+Cross-Sector+Collaboration+Against+Biological+Threats+in+an+Evolving+Global+Security+Environment/26874020.html <p>GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS), a global biodefense company, today highlighted the increasing importance of biological threat preparedness as allied nations confront an evolving security environment characterized by geopolitical conflict, artificial intelligence (AI) and synthetic biology and growing concern about the potential misuse of biological agents. Defense and public health leaders are addressing the heightened risks of biological incidents, whether naturally occurring outbreaks, accidental releases or deliberate acts, which represent a critical component of national resilience and security planning.</p> <p>In a recent event by the German Medical Association and German Ambulatory http://www.streetinsider.com/Press+Releases/Emergent+BioSolutions+Commits+to+Cross-Sector+Collaboration+Against+Biological+Threats+in+an+Evolving+Global+Security+Environment/26874020.html Wed, 05 Aug 2026 16:07:00 -0400 A.60012004 EBS O.01304637 O.01772186 http://www.streetinsider.com/Globe+Newswire/Emergent+BioSolutions+Commits+to+Cross-Sector+Collaboration+Against+Biological+Threats+in+an+Evolving+Global+Security+Environment/26874020.html <p>GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS), a global biodefense company, today highlighted the increasing importance of biological threat preparedness as allied nations confront an evolving security environment characterized by geopolitical conflict, artificial intelligence (AI) and synthetic biology and growing concern about the potential misuse of biological agents. Defense and public health leaders are addressing the heightened risks of biological incidents, whether naturally occurring outbreaks, accidental releases or deliberate acts, which represent a critical component of national resilience and security planning.</p> <p>In a recent event by the German Medical Association and German Ambulatory http://www.streetinsider.com/Globe+Newswire/Emergent+BioSolutions+Commits+to+Cross-Sector+Collaboration+Against+Biological+Threats+in+an+Evolving+Global+Security+Environment/26874020.html Wed, 05 Aug 2026 16:07:00 -0400 A.60012004 EBS O.01304637 O.01772186 http://www.streetinsider.com/Globe+Newswire/Emergent+BioSolutions+Commits+to+Cross-Sector+Collaboration+Against+Biological+Threats+in+an+Evolving+Global+Security+Environment/26874020.html <p>GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS), a global biodefense company, today highlighted the increasing importance of biological threat preparedness as allied nations confront an evolving security environment characterized by geopolitical conflict, artificial intelligence (AI) and synthetic biology and growing concern about the potential misuse of biological agents. Defense and public health leaders are addressing the heightened risks of biological incidents, whether naturally occurring outbreaks, accidental releases or deliberate acts, which represent a critical component of national resilience and security planning.</p> <p>In a recent event by the German Medical Association and German Ambulatory http://www.streetinsider.com/Globe+Newswire/Emergent+BioSolutions+Commits+to+Cross-Sector+Collaboration+Against+Biological+Threats+in+an+Evolving+Global+Security+Environment/26874020.html Wed, 05 Aug 2026 16:07:00 -0400 A.60012004 EBS O.01304637 O.01772186 http://www.streetinsider.com/Globe+Newswire/Emergent+BioSolutions+Commits+to+Cross-Sector+Collaboration+Against+Biological+Threats+in+an+Evolving+Global+Security+Environment/26874020.html <p>GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS), a global biodefense company, today highlighted the increasing importance of biological threat preparedness as allied nations confront an evolving security environment characterized by geopolitical conflict, artificial intelligence (AI) and synthetic biology and growing concern about the potential misuse of biological agents. Defense and public health leaders are addressing the heightened risks of biological incidents, whether naturally occurring outbreaks, accidental releases or deliberate acts, which represent a critical component of national resilience and security planning.</p> <p>In a recent event by the German Medical Association and German Ambulatory http://www.streetinsider.com/Globe+Newswire/Emergent+BioSolutions+Commits+to+Cross-Sector+Collaboration+Against+Biological+Threats+in+an+Evolving+Global+Security+Environment/26874020.html Wed, 05 Aug 2026 16:07:00 -0400 A.60012004 EBS O.01304637 O.01772186 http://www.streetinsider.com/Globe+Newswire/Emergent+BioSolutions+Commits+to+Cross-Sector+Collaboration+Against+Biological+Threats+in+an+Evolving+Global+Security+Environment/26874020.html <p>GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS), a global biodefense company, today highlighted the increasing importance of biological threat preparedness as allied nations confront an evolving security environment characterized by geopolitical conflict, artificial intelligence (AI) and synthetic biology and growing concern about the potential misuse of biological agents. Defense and public health leaders are addressing the heightened risks of biological incidents, whether naturally occurring outbreaks, accidental releases or deliberate acts, which represent a critical component of national resilience and security planning.</p> <p>In a recent event by the German Medical Association and German Ambulatory http://www.streetinsider.com/Globe+Newswire/Emergent+BioSolutions+Commits+to+Cross-Sector+Collaboration+Against+Biological+Threats+in+an+Evolving+Global+Security+Environment/26874020.html Wed, 05 Aug 2026 16:07:00 -0400 A.60012004 EBS O.01304637 O.01772186 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Emergent+BioSolutions+++++For%3A+Aug+05/26874040.html si-local-file:///var/storage/secattach/20260805/26874040.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Emergent+BioSolutions+++++For%3A+Aug+05/26874040.html Wed, 05 Aug 2026 16:07:00 -0400 EBS O.01772186 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Emergent+BioSolutions+++++For%3A+Aug+05/26874040.html si-local-file:///var/storage/secattach/20260805/26874040.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Emergent+BioSolutions+++++For%3A+Aug+05/26874040.html Wed, 05 Aug 2026 16:07:00 -0400 EBS O.01772186 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Emergent+BioSolutions++++++++++++++++++Filed+by%3A+VANGUARD+CAPITAL+MANAGEMENT+LLC/26848217.html si-local-file:///var/storage/secattach/20260731/26848217.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Emergent+BioSolutions++++++++++++++++++Filed+by%3A+VANGUARD+CAPITAL+MANAGEMENT+LLC/26848217.html Fri, 31 Jul 2026 10:21:00 -0400 EBS O.01772186 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Emergent+BioSolutions++++++++++++++++++Filed+by%3A+VANGUARD+CAPITAL+MANAGEMENT+LLC/26848217.html si-local-file:///var/storage/secattach/20260731/26848217.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Emergent+BioSolutions++++++++++++++++++Filed+by%3A+VANGUARD+CAPITAL+MANAGEMENT+LLC/26848217.html Fri, 31 Jul 2026 10:21:00 -0400 EBS O.01772186 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Emergent+BioSolutions++++++++++++++++++Filed+by%3A+BlackRock%2C+Inc./26827865.html si-local-file:///var/storage/secattach/20260728/26827865.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Emergent+BioSolutions++++++++++++++++++Filed+by%3A+BlackRock%2C+Inc./26827865.html Tue, 28 Jul 2026 16:45:00 -0400 EBS O.01772186 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Emergent+BioSolutions++++++++++++++++++Filed+by%3A+BlackRock%2C+Inc./26827865.html si-local-file:///var/storage/secattach/20260728/26827865.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Emergent+BioSolutions++++++++++++++++++Filed+by%3A+BlackRock%2C+Inc./26827865.html Tue, 28 Jul 2026 16:45:00 -0400 EBS O.01772186 http://www.streetinsider.com/Press+Releases/Emergent+BioSolutions+to+Report+Second+Quarter+2026+Financial+Results+on+August+5%2C+2026/26801484.html <p>GAITHERSBURG, Md., July 22, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, August 5, 2026, at 5:00 p.m. eastern time to discuss the financial results for the second quarter of 2026.</p> <p>Participants can access the conference call live via <a href="https://www.globenewswire.com/Tracker?data=-UcFlJgMadG9WRHlhLP3IC0tWlqaBpGpdCLMC2I6EG65V1SwUAJumh0MdDaKhx3kFDMyYMLDcOxR2ezmW3bX9JScHnI5CsHdCdQWAp8Ye2s=" rel="nofollow" target="_blank">webcast</a> and also by visiting the <a href="https://www.globenewswire.com/Tracker?data=VCxN_WvLbEpg4M36LXrFMw5Px3BHjpcqOJsraZwrfhcwEKssWbGCXSckBGwuImfiRS8PFSWZr4W6m1RKltFjYKoD_WAgpwsuV4D9tarodMo=" rel="nofollow" target="_blank">Investors</a> page of Emergent’s website. To participate via telephone, please register in advance at this <a href="https://www.globenewswire.com/Tracker?data=Ewca_yrgrimj6Yzv81cXUY21A2yuiDiNTW9Fqq5rmqKSgbwpktg-V93M24xK-_Pcw7Z9LXNn5cgmOaLOvQXLsCae9ECSbLkcuDyg10Eo275lFQibZu_XU9wFBmLx1RyWlcbySbWxBrKZM05SVTWdQ9kZthQ6wi5wTtfe6iwwPVc=" rel="nofollow" target="_blank">link</a>. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the http://www.streetinsider.com/Press+Releases/Emergent+BioSolutions+to+Report+Second+Quarter+2026+Financial+Results+on+August+5%2C+2026/26801484.html Wed, 22 Jul 2026 16:01:00 -0400 EBS http://www.streetinsider.com/Globe+Newswire/Emergent+BioSolutions+to+Report+Second+Quarter+2026+Financial+Results+on+August+5%2C+2026/26801484.html <p>GAITHERSBURG, Md., July 22, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, August 5, 2026, at 5:00 p.m. eastern time to discuss the financial results for the second quarter of 2026.</p> <p>Participants can access the conference call live via <a href="https://www.globenewswire.com/Tracker?data=-UcFlJgMadG9WRHlhLP3IC0tWlqaBpGpdCLMC2I6EG65V1SwUAJumh0MdDaKhx3kFDMyYMLDcOxR2ezmW3bX9JScHnI5CsHdCdQWAp8Ye2s=" rel="nofollow" target="_blank">webcast</a> and also by visiting the <a href="https://www.globenewswire.com/Tracker?data=VCxN_WvLbEpg4M36LXrFMw5Px3BHjpcqOJsraZwrfhcwEKssWbGCXSckBGwuImfiRS8PFSWZr4W6m1RKltFjYKoD_WAgpwsuV4D9tarodMo=" rel="nofollow" target="_blank">Investors</a> page of Emergent’s website. To participate via telephone, please register in advance at this <a href="https://www.globenewswire.com/Tracker?data=Ewca_yrgrimj6Yzv81cXUY21A2yuiDiNTW9Fqq5rmqKSgbwpktg-V93M24xK-_Pcw7Z9LXNn5cgmOaLOvQXLsCae9ECSbLkcuDyg10Eo275lFQibZu_XU9wFBmLx1RyWlcbySbWxBrKZM05SVTWdQ9kZthQ6wi5wTtfe6iwwPVc=" rel="nofollow" target="_blank">link</a>. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the http://www.streetinsider.com/Globe+Newswire/Emergent+BioSolutions+to+Report+Second+Quarter+2026+Financial+Results+on+August+5%2C+2026/26801484.html Wed, 22 Jul 2026 16:01:00 -0400 EBS http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Erste+Group+Bank+AGADR++++++++++++++/26749584.html si-local-file:///var/storage/secattach/20260709/26749584.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Erste+Group+Bank+AGADR++++++++++++++/26749584.html Thu, 09 Jul 2026 06:03:00 -0400 EBKDY EBS O.04766983